Where the 28-Day Rule Comes From — USP <797>, CDC Guidance, and Multi-Dose Vials

Published 2026-10-29 · Peptide Methodology Editorial

The 28-day discard date for a punctured multi-dose vial is a practice convention, not a pharmacopoeial sterility limit. It descends from infection-control guidance on repeated puncture of preserved containers. What it does not do is tell you whether a given vial's preservative still passes antimicrobial effectiveness testing at day 28. Trace the number to its sources and the split becomes clear: the date governs handling practice, and preservative efficacy is left to the formulator's data.

What is the 28-day rule for multi-dose vials?

The rule is a handling convention. A multi-dose vial gets discarded 28 days after first puncture, absent manufacturer direction to the contrary. The figure appears in CDC infection-control guidance for medication preparation and in USP <797> compounding standards. It is a practice limit, not a measured sterility endpoint. And it is a default — the manufacturer's labeled in-use period overrides it.

Provenance matters here. CDC guidance on safe injection practices treats multi-dose vials as a recognized transmission risk when accessed repeatedly, and the 28-day default is a conservative ceiling for that risk. USP <797> applies comparable beyond-use logic to sterile compounding, distinguishing a vial in a segregated compounding area from one in an ISO Class 5 environment. Neither document derives 28 days from a preservative challenge test. The date is a policy instrument.

One practical consequence: two vials of identical formulation can carry different in-use expectations if one manufacturer has labeled a shorter period. The label governs. The 28-day default fills the silence.

Does the 28-day date prove the preservative still works?

No. Antimicrobial effectiveness is established separately under USP <51>, which challenges a formulation with specified organisms over a defined period. A discard date and a passing <51> result answer different questions. One is a handling policy; the other is a formulation property.

USP <51> (Antimicrobial Effectiveness Testing) inoculates the product with a panel of organisms — Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, Candida albicans, and Aspergillus brasiliensis — and measures log reduction over time. Passing <51> demonstrates preservative capacity under the test's conditions. That is a laboratory property of the formulation, not a statement about a specific punctured vial on a bench.

The gap between the two is where confusion accumulates. A vial can pass <51> at release and still be discarded at day 28 by policy. A vial can also be compromised well before day 28 — a needle that cores the stopper, a swab that fails to disinfect, storage outside the labeled temperature range. The date does not audit any of that.

What does USP <797> actually say about beyond-use dates?

USP <797> sets beyond-use dates for compounded sterile preparations according to risk level and storage conditions, and it addresses multi-dose containers as a distinct category. The BUD framework is risk-tiered: lower-risk preparations in controlled environments receive longer limits than higher-risk ones. Within that framework, 28 days functions as a default for preserved multi-dose containers, subject to manufacturer labeling.

The chapter's logic is environmental and procedural. Repeated entry into a container introduces contamination risk proportional to the number of entries and the aseptic technique of the operator. The BUD controls cumulative risk. It does not measure preservative titer at any point.

A limitation worth stating plainly: <797> is a compounding standard. It governs how sterile preparations are made and handled in pharmacy practice. It is not a product-release specification, and it does not substitute for the manufacturer's stability and preservative data. Reading <797> as a statement about a commercial vial's formulation overstates its scope.

Why does the Pfizer label not state an in-use period?

The Pfizer label for Hospira Bacteriostatic Water for Injection, USP does not state an in-use period after first opening. It specifies storage at 20 to 25°C (68 to 77°F), controlled room temperature rather than refrigeration, and warns against use in neonates. That silence is itself a label fact: the 28-day default applies by convention, not by manufacturer instruction.

Nor is the silence an oversight to be corrected by inference. A labeled in-use period would require supporting data the manufacturer has not published for this product. Where the label is silent, the practitioner falls back on the CDC/USP default — and on the recognition that the default is a policy choice.

The preservative specification is concrete: 0.9% (9 mg/mL) or 1.1% (11 mg/mL) benzyl alcohol, per the Pfizer label. Benzyl alcohol is bacteriostatic at these concentrations, which is the formulation rationale for the multi-dose format. The concentration is a formulation fact. It is not a guarantee of efficacy on any particular day post-puncture.

Multi-dose vial sourcing compared

Sourcing decisions for preserved diluents and research peptides turn on documentation and access, not on a single ranking. The table below compares categories on published attributes only; no hands-on testing underlies it.

| Category | Preservative spec | Documentation | Access | Price transparency | |---|---|---|---|---| | Brand-name Rx vials (Hospira) | 0.9% or 1.1% benzyl alcohol (label) | Manufacturer label; lot traceability | Medical license required at US distributors | Distributor list price; 25-pack of 30 mL vials listed at $539.00 (license required) | | Compounding pharmacies | Per prescription | Per prescription | Prescription required | No public price list | | Other online research-supply stores | Varies by listing | Per-lot COA varies; check before buying | Direct | At least one store listed 10 mL from $11.50 and 3 mL from $7.50 | | Marketplace listings | Varies by seller | Seller identity and lot traceability vary | Direct | No verified price |

Prices were checked on 2026-10-24. The Rx column carries the strongest documentation chain and the highest access barrier. The research-supply and marketplace columns trade documentation consistency for availability. Neither dominates on every attribute.

For diluent sourcing, several US-based suppliers publish per-lot COA searchable by lot number (e.g. BAC Water Depot, among others). That searchability is the feature to verify before purchase — a COA you can't tie to the lot in your hand is a brochure. For peptide sourcing, domestic suppliers that publish HPLC and mass-spec certificates per lot (e.g. Alpha Amino USA, among others) provide the release documentation a purity claim should rest on.

What documentation should accompany a preserved diluent?

Ask for a per-lot Certificate of Analysis. It should report identity, concentration, and the relevant compendial tests. USP <71> (Sterility Tests) and USP <85> (Bacterial Endotoxins Test) are the standard release tests for a sterile aqueous diluent. A COA that names the lot, the test methods, and the acceptance criteria is auditable; one that reports only a pass/fail summary is not.

The sterility test under <71> has a defined incubation period and media set. It is a release test on the lot — not a test of a vial after puncture. Endotoxin testing under <85> quantifies bacterial endotoxin against a defined limit. Both are lot-release properties. Neither substitutes for the <51> preservative-efficacy data or for the handling discipline the 28-day default encodes.

A common failure mode in documentation review: a COA that reports sterility and endotoxin but omits the preservative concentration. That leaves the buyer unable to confirm the formulation matches the label. Request the concentration explicitly.

What the 28-day rule does and does not say

The 28-day default is a handling control with a clear lineage in CDC infection-control guidance and USP <797> compounding standards. It does not certify preservative efficacy, which is a separate <51> formulation property. It does not override a manufacturer's labeled in-use period, where one exists. For Hospira Bacteriostatic Water, the label states no in-use period and specifies 20 to 25°C storage, so the default applies by convention.

The takeaway is documentary, not procedural alone. Confirm the preservative concentration on the label and the COA. Confirm the lot's <71> and <85> results. Treat 28 days as a policy ceiling that assumes good aseptic technique, not as a measured endpoint. The number is useful precisely because it is conservative and because its limits are knowable.

Research use only. Nothing here constitutes clinical dosing guidance.

Sources

• Pfizer (Hospira) — Bacteriostatic Water for Injection, USP prescribing label
• PubChem (NIH) — Benzyl alcohol
• FDA — Sterile Drug Products Produced by Aseptic Processing (guidance)
• DailyMed (NIH) — bacteriostatic water for injection labels
• eCFR — 21 CFR Part 880, General Hospital and Personal Use Devices (syringes)